Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma, Follicular 1Adenocarcinoma Of Esophagus 1

Interventions

pasireotide 4Temozolomide 2lutetium Lu 177 dotatate 1farletuzumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tranexamic Acid 1Thyrotropin-Releasing Hormone 1TBR-760 1Rosiglitazone 1Nivolumab 1Microarray Analysis 1Lapatinib 1Ipilimumab 1DNA Methylation 1Complementary Therapies 1Capecitabine 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pituitary Neoplasms × Rosiglitazone × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡